FDA Approval: EMGALITY (GALCANEZUMAB-GNLM) — Type 1 - New Molecular Entity
Policy FDA-BLA761063 · Neurology
Emgality (galcanezumab) is likely to receive a new J-code for billing under Medicare Part B since it is an injectable drug. The drug may be eligible for ASP+6% reimbursement, given its injectable stat